News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
488,059 Results
Type
Article (8770)
Company Profile (140)
Press Release (479051)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (167308)
Career Advice (307)
Deals (25788)
Drug Delivery (9)
Drug Development (53272)
Employer Resources (14)
FDA (9824)
Job Trends (8617)
News (239194)
Policy (17996)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (582)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (97)
Alliances (33321)
ALS (119)
Alzheimer's disease (1023)
Antibody-drug conjugate (ADC) (263)
Approvals (10447)
Artificial intelligence (342)
ASCO (160)
Autoimmune disease (207)
Automation (29)
Bankruptcy (263)
Best Places to Work (6998)
BIO (36)
Biologics (2)
BIOSECURE Act (1)
Biosimilars (109)
BioSpace Insights (20)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (29)
Breast cancer (511)
Cancer (3664)
Cardiovascular disease (217)
Career advice (248)
Career pathing (1)
CAR-T (172)
Celiac Disease (1)
Cell therapy (493)
Cervical cancer (34)
Clinical research (48204)
Collaboration (1274)
Commercialization (3)
Compensation (1468)
Complete response letters (34)
COVID-19 (777)
CRISPR (63)
C-suite (756)
Cystic fibrosis (85)
Data (5732)
Denatured (4)
Depression (106)
Dermatology (61)
Diabetes (343)
Diagnostics (4215)
Digital health (40)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (164)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (163)
Earnings (73824)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87967)
Executive appointments (706)
FDA (12500)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (24)
Funding (942)
Gene editing (125)
Generative AI (12)
Gene therapy (321)
GLP-1 (293)
Government (965)
Grass and pollen (2)
Guidances (281)
Healthcare (9437)
Hematology (94)
HIV (52)
Huntington's disease (24)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (56)
Indications (160)
Infectious disease (965)
Inflammatory bowel disease (127)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (257)
Interviews (42)
IPO (12407)
IRA (2)
Job creations (1978)
Job search strategy (237)
JPM (2)
Kidney cancer (16)
Layoffs (62)
Legal (5216)
Licensing (8)
Liver cancer (44)
Longevity (17)
Lung cancer (512)
Lymphoma (250)
Machine learning (28)
Management (3)
Manufacturing (539)
Marketing (8)
MASH (118)
Medical device (8757)
Medtech (8906)
Mergers & acquisitions (14418)
Metabolic disorders (707)
mRNA (56)
Multiple sclerosis (103)
NASH (4)
Neurodegenerative disease (240)
Neuropsychiatric disorders (41)
Neuroscience (1946)
Neurotech (1)
NextGen: Class of 2026 (3213)
Non-profit (904)
Obesity (224)
Opinion (11)
Ovarian cancer (159)
Pain (181)
Pancreatic cancer (196)
Parkinson's disease (225)
Partnered (13)
Patents (479)
Patient recruitment (515)
Peanut (31)
People (41436)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15595)
Phase 2 (21538)
Phase 3 (14507)
Pipeline (7398)
Policy (19)
Postmarket research (1573)
Preclinical (6616)
Press Release (34)
Prostate cancer (189)
Psychedelics (8)
Radiopharmaceuticals (193)
Rare diseases (577)
Real estate (3032)
Recruiting (6)
Regulatory (14933)
Reports (22)
Research institute (671)
Resumes & cover letters (46)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (101)
Series A (161)
Series B (125)
Service/supplier (5)
Sickle cell disease (63)
Special edition (1)
Spinal muscular atrophy (89)
Sponsored (6)
Startups (2042)
Stomach cancer (3)
Supply chain (50)
Vaccines (326)
Venture capital (18)
Weight loss (73)
Women's health (79)
Date
Last 7 days (221)
Last 30 days (1543)
Last 365 days (19188)
2026 (12433)
2025 (19438)
2024 (23173)
2023 (26746)
2022 (34862)
2021 (37442)
2020 (33631)
2019 (23500)
2018 (17609)
2017 (18932)
2016 (18117)
2015 (24484)
2014 (21869)
2013 (18288)
2012 (20312)
2011 (20548)
2010 (20406)
Location
Africa (229)
Alabama (73)
Alaska (2)
Arizona (305)
Arkansas (11)
Asia (18142)
Australia (2171)
California (12026)
Canada (3157)
China (539)
Colorado (488)
Connecticut (411)
Delaware (208)
Europe (25249)
Florida (1792)
Georgia (382)
Hawaii (3)
Idaho (48)
Illinois (701)
India (51)
Indiana (314)
Iowa (15)
Japan (404)
Kansas (101)
Kentucky (30)
Louisiana (31)
Maine (30)
Maryland (1206)
Massachusetts (7908)
Michigan (307)
Minnesota (565)
Mississippi (4)
Missouri (83)
Montana (20)
Nebraska (11)
Nevada (116)
New Hampshire (60)
New Jersey (2640)
New Mexico (12)
New York (2868)
North Carolina (1282)
North Dakota (4)
Northern California (6027)
Ohio (279)
Oklahoma (14)
Oregon (16)
Pennsylvania (2254)
Puerto Rico (20)
Rhode Island (31)
South America (412)
South Carolina (76)
South Dakota (1)
Southern California (4990)
Tennessee (120)
Texas (1947)
United States (39093)
Utah (362)
Vermont (1)
Virginia (153)
Washington D.C. (38)
Washington State (933)
West Virginia (1)
Wisconsin (76)
Wyoming (1)
488,059 Results for "neurelis inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
NEURELIS TO PRESENT ANALYSES OF IMMEDIATE-USE SEIZURE TREATMENT AT THE AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING
April 17, 2026
·
8 min read
Press Releases
Neurelis Provides Business Update Highlighting Transformational 2025 Results
January 13, 2026
·
9 min read
Press Releases
NEURELIS TO PRESENT CLINICAL DATA AT AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
December 8, 2025
·
12 min read
Press Releases
NEURELIS TO PARTICIPATE IN SOFIE’S JOURNEY EPILEPSY AWARENESS DAY AND EDUCATION EXPO AT DISNEYLAND® RESORT
November 11, 2025
·
7 min read
Press Releases
NeurAxis, Inc. Announces Preferred Stock Dividend
April 10, 2026
·
3 min read
Press Releases
Neurelis to Highlight Data from a Study of Diazepam Nasal Spray in Pediatric Patients at the Child Neurology Society Annual Meeting
October 9, 2025
·
8 min read
Press Releases
NEURELIS TO PRESENT STUDY OF NRL-1049, A RHO KINASE (ROCK) INHIBITOR WITH POTENTIAL TO TREAT SYMPTOMATIC CEREBRAL CAVERNOUS MALFORMATIONS (CCM), AT ANNUAL CCM MEETING
November 7, 2025
·
7 min read
Press Releases
NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026
July 28, 2026
·
1 min read
Biotech Beach
NEURELIS ANNOUNCES PRESENTATIONS AT THE AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
Neurelis, Inc., today announced that the company will present six poster presentations at the American Epilepsy Society (AES) Annual Meeting held in Orlando, Florida from December 1 – 5, 2023.
December 1, 2023
·
11 min read
Biotech Beach
Neurelis, Inc. to Participate in the 6th Annual Evercore ISI HealthCONx Conference
Neurelis, Inc., a company focused on epilepsy and orphan neurologic disorders, today announced that corporate leadership will participate in and host one-on-one investor meetings at the 6th Annual Evercore ISI HealthCONx Conference, to be held in Miami from November 28-30, 2023.
November 16, 2023
·
1 min read
1 of 48,806
Next
